CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 50 target
Drug / intervention
fluzoparil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04552977
NCT04552977Phase 2Unknown
CompareCT.gov

A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma

Shandong Cancer Hospital and Institute·interventional·Posted Sep 17, 2020·Updated Sep 17, 2020

In Brief

A Phase 2 clinical trial evaluating fluzoparil and temozolomide for Glioblastoma. Targeting 50 participants.

Detailed Summary

This is a one arm, open, single center phase II study. The main purpose of this study was to evaluate the efficacy and safety of fluzoparil combined with temozolomide in patients with recurrent glioblastoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
Countries--
Collaborators--

Timeline

Phase 2UnknownOverdue
202120222023202420252026
First PostedSep 17, 2020
Enrollment StartSep 1, 2020
Primary CompletionAug 1, 2021
Study CompletionAug 1, 2022
TodayJul 1, 2026
Enrollment to primary: 11 monthsPosted 5.8 years ago

Interventions

fluzoparildrug

a PARP1 inhibitor

temozolomidedrug

an alkylating chemotherapeutic agent